GlassScriptPhysician profile
Huiming Hon
NPI 1780854109
$159,076.52
in general payments reported to CMS, 2019-2025
42 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,223 · 2020: $3,929 · 2021: $5,740 · 2022: $8,959 · 2023: $18K · 2024: $39K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Consulting Fee: $11K · Travel and Lodging: $9,928 · Food and Beverage: $9,483 · Honoraria: $5,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,399.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,920.00 |
| Consulting Fee | $11,362.50 |
| Travel and Lodging | $9,928.41 |
| Food and Beverage | $9,482.55 |
| Honoraria | $5,132.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $48,644.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $43,914.91 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $33,691.45 | 2023-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $19,075.51 | 2019-2025 | Livdelzi |
| Abbvie INC. | $6,230.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,714.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,190.76 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $707.30 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $326.93 | 2019-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $264.31 | 2019-2024 | Dificid, Zinplava |
| Celgene Corporation | $258.35 | 2021-2024 | Zeposia |
| Amgen INC. | $215.86 | 2023-2025 | Uplizna, Amjevita, Avsola |
| Medtronic, INC. | $198.67 | 2022-2024 | Interstim |
| Mallinckrodt Hospital Products INC. | $167.37 | 2025 | Terlivaz |
| Genzyme Corporation | $135.51 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $131.29 | 2025 | Wegovy |
| Lilly USA, LLC | $129.26 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $83.23 | 2021-2023 | |
| Vivus LLC | $81.83 | 2022-2025 | Qsymia, Pancreaze |
| Celltrion USA INC. | $81.32 | 2024-2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $75.51 | 2019-2021 | |
| Allergan, INC. | $68.24 | 2019-2020 | |
| Intra-Sana Laboratories | $65.70 | 2021-2022 | |
| Sandoz INC. | $64.45 | 2023-2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $55.38 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $52.78 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $49.45 | 2022-2023 | Dupixent |
| Ambu INC. | $48.59 | 2020-2021 | |
| Pfizer INC. | $45.14 | 2019-2024 | |
| Ardelyx, INC. | $44.82 | 2023-2024 | Ibsrela |
| Braintree Laboratories, INC. | $41.92 | 2024-2025 | Suflave, Sutab |
| Shire North American Group INC | $40.97 | 2019 | |
| Kadmon Pharmaceuticals LLC | $25.97 | 2020 | |
| Dova Pharmaceuticals | $24.58 | 2019 | |
| Ferring Pharmaceuticals INC. | $23.59 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $18.36 | 2019 | |
| Fresenius Kabi USA, LLC | $17.66 | 2023 | Idacio |
| Orphalan INC | $17.13 | 2025 | Cuvrior |
| Baxter Healthcare | $16.64 | 2021 | |
| Daiichi Sankyo INC. | $13.55 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.40 | 2021 | |
| Evoke Pharma, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huiming Hon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.